IGF1 and atypical Rett syndrome: Trofinetide emerged as the highest-ranked peptide candidate, with a medicinal chemistry-adjusted network score of 1.387, representing an FDA-approved synthetic analog of glycyl-L-2-methylprolyl-L-glutamic acid (GPE), the C-terminal tripeptide of insulin-like growth factor-1 (IGF-1), currently indicated for Rett syndrome treatment.